WO2007134014A2
(en)
|
2006-05-05 |
2007-11-22 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating expression of gcgr
|
ES2620472T5
(es)
*
|
2006-10-18 |
2020-07-09 |
Ionis Pharmaceuticals Inc |
Compuestos antisentido
|
DK2149605T3
(da)
*
|
2007-03-22 |
2013-09-30 |
Santaris Pharma As |
Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
|
US8318496B2
(en)
*
|
2007-10-04 |
2012-11-27 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for improving cellular uptake of oligomeric compounds
|
US8846639B2
(en)
|
2008-04-04 |
2014-09-30 |
Isis Pharmaceutical, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
|
NZ592203A
(en)
|
2008-10-15 |
2013-01-25 |
Isis Pharmaceuticals Inc |
Modulation of factor 11 expression
|
CA2744987C
(en)
|
2008-12-02 |
2018-01-16 |
Chiralgen, Ltd. |
Method for the synthesis of phosphorus atom modified nucleic acids
|
BR112012000828A8
(pt)
|
2009-07-06 |
2017-10-10 |
Ontorii Inc |
Novas pró-drogas de ácido nucleico e métodos de uso das mesmas
|
EP3208347B1
(en)
|
2010-02-08 |
2019-08-14 |
Ionis Pharmaceuticals, Inc. |
Selective reduction of allelic variants
|
US8957040B2
(en)
|
2010-02-08 |
2015-02-17 |
Isis Pharmaceuticals, Inc. |
Selective reduction of allelic variants
|
EP3633038A3
(en)
|
2010-07-19 |
2020-07-29 |
Ionis Pharmaceuticals, Inc. |
Modulation of dystrophia myotonica-protein kinase (dmpk) expression
|
US8648053B2
(en)
|
2010-10-20 |
2014-02-11 |
Rosalind Franklin University Of Medicine And Science |
Antisense oligonucleotides that target a cryptic splice site in Ush1c as a therapeutic for Usher syndrome
|
US9920317B2
(en)
|
2010-11-12 |
2018-03-20 |
The General Hospital Corporation |
Polycomb-associated non-coding RNAs
|
JP6336755B2
(ja)
|
2010-11-12 |
2018-06-06 |
ザ ジェネラル ホスピタル コーポレイション |
ポリコームに関連する非コードrna
|
EP3521451A1
(en)
|
2010-11-17 |
2019-08-07 |
Ionis Pharmaceuticals, Inc. |
Modulation of alpha synuclein expression
|
EP2673361B1
(en)
|
2011-02-08 |
2016-04-13 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
WO2012161806A1
(en)
*
|
2011-02-25 |
2012-11-29 |
Isis Pharmaceuticals, Inc. |
Modulation of stat3 expression
|
RU2667524C2
(ru)
*
|
2011-04-21 |
2018-09-21 |
Ионис Фармасьютикалз, Инк. |
Модулирование экспрессии вируса гепатита b (hbv)
|
US9353371B2
(en)
|
2011-05-02 |
2016-05-31 |
Ionis Pharmaceuticals, Inc. |
Antisense compounds targeting genes associated with usher syndrome
|
RU2014105311A
(ru)
|
2011-07-19 |
2015-08-27 |
Уэйв Лайф Сайенсес Пте. Лтд. |
Способы синтеза функционализованных нуклеиновых кислот
|
WO2013022967A1
(en)
|
2011-08-11 |
2013-02-14 |
Isis Pharmaceuticals, Inc. |
Gapped oligomeric compounds comprising 5'-modified deoxyribonucleosides in the gap and uses thereof
|
WO2013040429A1
(en)
|
2011-09-14 |
2013-03-21 |
Rana Therapeutics Inc. |
Multimeric oligonucleotide compounds
|
US9243291B1
(en)
*
|
2011-12-01 |
2016-01-26 |
Isis Pharmaceuticals, Inc. |
Methods of predicting toxicity
|
US20150315595A1
(en)
*
|
2012-03-12 |
2015-11-05 |
Santaris Pharma A/S |
Compositions and Methods for Modulation of ATXN3 Expression
|
EP2839006B1
(en)
*
|
2012-04-20 |
2018-01-03 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
AU2013262656A1
(en)
|
2012-05-16 |
2015-01-22 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating UTRN expression
|
JP2015523854A
(ja)
|
2012-05-16 |
2015-08-20 |
ラナ セラピューティクス インコーポレイテッド |
Smn遺伝子ファミリー発現を調節するための組成物及び方法
|
WO2013173605A1
(en)
*
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating pten expression
|
AP2014008100A0
(en)
|
2012-05-16 |
2014-12-31 |
Gen Hospital Corp |
Compositions and methods for modulating hemoglobingene family expression
|
US10837014B2
(en)
|
2012-05-16 |
2020-11-17 |
Translate Bio Ma, Inc. |
Compositions and methods for modulating SMN gene family expression
|
WO2013173608A1
(en)
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating mecp2 expression
|
US10174323B2
(en)
|
2012-05-16 |
2019-01-08 |
The General Hospital Corporation |
Compositions and methods for modulating ATP2A2 expression
|
US9574193B2
(en)
|
2012-05-17 |
2017-02-21 |
Ionis Pharmaceuticals, Inc. |
Methods and compositions for modulating apolipoprotein (a) expression
|
US20160002624A1
(en)
|
2012-05-17 |
2016-01-07 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide compositions
|
LT2855500T
(lt)
|
2012-05-24 |
2020-11-10 |
Ionis Pharmaceuticals, Inc. |
Būdai ir kompozicijos, skirti apolipoproteino (a) raiškos moduliacijai
|
US9487780B2
(en)
|
2012-06-01 |
2016-11-08 |
Ionis Pharmaceuticals, Inc. |
Antisense compounds targeting genes associated with fibronectin
|
WO2013181665A1
(en)
*
|
2012-06-01 |
2013-12-05 |
Isis Pharmaceuticals, Inc. |
Antisense compounds targeting genes associated with fibronectin
|
MX356830B
(es)
|
2012-07-13 |
2018-06-15 |
Shin Nippon Biomedical Laboratories Ltd |
Adyuvante de acido nucleico quiral.
|
JP6268157B2
(ja)
|
2012-07-13 |
2018-01-24 |
株式会社Wave Life Sciences Japan |
不斉補助基
|
SG10201912895PA
(en)
|
2012-07-13 |
2020-02-27 |
Wave Life Sciences Ltd |
Chiral control
|
US20150247141A1
(en)
|
2012-09-14 |
2015-09-03 |
Rana Therapeutics, Inc. |
Multimeric oligonucleotide compounds
|
US9695418B2
(en)
|
2012-10-11 |
2017-07-04 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and uses thereof
|
WO2014059341A2
(en)
|
2012-10-12 |
2014-04-17 |
Isis Pharmaceuticals, Inc. |
Antisense compounds and uses thereof
|
LT2929031T
(lt)
*
|
2012-12-05 |
2018-02-12 |
Alnylam Pharmaceuticals, Inc. |
Pcsk9 irna kompozicijos ir jų naudojimo būdai
|
WO2014132671A1
(en)
*
|
2013-03-01 |
2014-09-04 |
National University Corporation Tokyo Medical And Dental University |
Chimeric single-stranded antisense polynucleotides and double-stranded antisense agent
|
KR102605775B1
(ko)
*
|
2013-03-14 |
2023-11-29 |
알닐람 파마슈티칼스 인코포레이티드 |
보체 성분 C5 iRNA 조성물 및 그 이용 방법
|
IL284593B2
(en)
|
2013-05-01 |
2023-02-01 |
Ionis Pharmaceuticals Inc |
Compositions and methods for modulation of hbv and ttr expression
|
TW201536329A
(zh)
|
2013-08-09 |
2015-10-01 |
Isis Pharmaceuticals Inc |
用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
|
US11162096B2
(en)
|
2013-10-14 |
2021-11-02 |
Ionis Pharmaceuticals, Inc |
Methods for modulating expression of C9ORF72 antisense transcript
|
US20170268000A1
(en)
|
2013-12-02 |
2017-09-21 |
Ionis Pharmaceuticals, Inc. |
Antisense compounds and uses thereof
|
JPWO2015108046A1
(ja)
|
2014-01-15 |
2017-03-23 |
株式会社新日本科学 |
抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
|
JPWO2015108047A1
(ja)
|
2014-01-15 |
2017-03-23 |
株式会社新日本科学 |
免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
|
WO2015108048A1
(ja)
|
2014-01-15 |
2015-07-23 |
株式会社新日本科学 |
抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
|
KR102423317B1
(ko)
|
2014-01-16 |
2022-07-22 |
웨이브 라이프 사이언시스 리미티드 |
키랄 디자인
|
JP6902869B2
(ja)
|
2014-03-19 |
2021-07-14 |
アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. |
アタキシン2の発現を調節するための組成物
|
WO2015143245A1
(en)
|
2014-03-19 |
2015-09-24 |
Isis Pharmaceuticals, Inc. |
Methods for modulating ataxin 2 expression
|
SG11201608109TA
(en)
|
2014-04-01 |
2016-10-28 |
Ionis Pharmaceuticals Inc |
Compositions for modulating sod-1 expression
|
BR112016022593B1
(pt)
|
2014-05-01 |
2022-04-26 |
Ionis Pharmaceuticals, Inc |
Compostos oligoméricos, composições que os compreendem, e usos dos mesmos
|
WO2015187989A1
(en)
|
2014-06-04 |
2015-12-10 |
Isis Pharmaceuticals, Inc. |
Antisense compounds targeting apolipoprotein e receptor 2
|
GB201410693D0
(en)
|
2014-06-16 |
2014-07-30 |
Univ Southampton |
Splicing modulation
|
EP3161159B1
(en)
|
2014-06-25 |
2020-08-05 |
The General Hospital Corporation |
Targeting human satellite ii (hsatii)
|
CA2960728C
(en)
|
2014-09-18 |
2023-06-06 |
The University Of British Columbia |
Allele-specific therapy for huntington disease haplotypes
|
KR102620328B1
(ko)
|
2014-10-03 |
2024-01-02 |
콜드스프링하버러보러토리 |
핵 유전자 산출량의 표적화 증강
|
CA2966044A1
(en)
|
2014-10-30 |
2016-05-06 |
The General Hospital Corporation |
Methods for modulating atrx-dependent gene repression
|
JP2017536366A
(ja)
*
|
2014-11-19 |
2017-12-07 |
ロシュ イノベーション センター コペンハーゲン エーエス |
Lnaキラルホスホロチオエート
|
JP6689279B2
(ja)
*
|
2014-12-16 |
2020-05-20 |
ロシュ イノベーション センター コペンハーゲン エーエス |
キラル毒性のスクリーニング方法
|
US10793855B2
(en)
|
2015-01-06 |
2020-10-06 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of C9ORF72 antisense transcript
|
US10538763B2
(en)
|
2015-01-16 |
2020-01-21 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulation of DUX4
|
EP3254104B1
(en)
|
2015-02-04 |
2021-08-25 |
Bristol-Myers Squibb Company |
Methods of selecting therapeutic molecules
|
RU2017127609A
(ru)
|
2015-02-04 |
2019-03-04 |
Ф. Хоффманн-Ля Рош Аг |
Антисмысловые олигомеры тау-белка и их применение
|
WO2016130963A1
(en)
*
|
2015-02-13 |
2016-08-18 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating rna
|
EP3256591A4
(en)
|
2015-02-13 |
2018-08-08 |
Translate Bio Ma, Inc. |
Hybrid oligonucleotides and uses thereof
|
US11129844B2
(en)
|
2015-03-03 |
2021-09-28 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating MECP2 expression
|
WO2016149455A2
(en)
|
2015-03-17 |
2016-09-22 |
The General Hospital Corporation |
The rna interactome of polycomb repressive complex 1 (prc1)
|
US10407678B2
(en)
|
2015-04-16 |
2019-09-10 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of C9ORF72 antisense transcript
|
MA43072A
(fr)
|
2015-07-22 |
2018-05-30 |
Wave Life Sciences Ltd |
Compositions d'oligonucléotides et procédés associés
|
US10533175B2
(en)
|
2015-09-25 |
2020-01-14 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating Ataxin 3 expression
|
KR20220105174A
(ko)
|
2015-10-09 |
2022-07-26 |
유니버시티 오브 사우스앰톤 |
유전자 발현의 조절 및 탈조절된 단백질 발현의 스크리닝
|
WO2017096395A1
(en)
|
2015-12-04 |
2017-06-08 |
Ionis Pharmaceuticals, Inc. |
Methods of treating breast cancer
|
WO2017106377A1
(en)
|
2015-12-14 |
2017-06-22 |
Cold Spring Harbor Laboratory |
Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome
|
US11096956B2
(en)
|
2015-12-14 |
2021-08-24 |
Stoke Therapeutics, Inc. |
Antisense oligomers and uses thereof
|
CA3006599A1
(en)
|
2016-01-05 |
2017-07-13 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing lrrk2 expression
|
WO2017142054A1
(ja)
|
2016-02-17 |
2017-08-24 |
国立大学法人東京工業大学 |
人工ヌクレオシド及び人工ヌクレオチド並びに人工オリゴヌクレオチド
|
WO2017161168A1
(en)
|
2016-03-16 |
2017-09-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of dyrk1b expression
|
EP3429690A4
(en)
|
2016-03-16 |
2019-10-23 |
Ionis Pharmaceuticals, Inc. |
METHOD FOR MODULATING KEAP1
|
MA45270A
(fr)
|
2016-05-04 |
2017-11-09 |
Wave Life Sciences Ltd |
Compositions d'oligonucléotides et procédés associés
|
MA45496A
(fr)
|
2016-06-17 |
2019-04-24 |
Hoffmann La Roche |
Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b
|
EP3471781A4
(en)
|
2016-06-17 |
2020-05-06 |
Ionis Pharmaceuticals, Inc. |
MODULATING THE GYS1 EXPRESSION
|
WO2018055577A1
(en)
*
|
2016-09-23 |
2018-03-29 |
Synthena Ag |
Mixed tricyclo-dna, 2'-modified rna oligonucleotide compositions and uses thereof
|
US11118179B2
(en)
|
2016-09-23 |
2021-09-14 |
Synthena Ag |
Mixed tricyclo-DNA, 2′-modified RNA oligonucleotide compositions and uses thereof
|
EP3521430A4
(en)
|
2016-09-29 |
2020-05-20 |
National University Corporation Tokyo Medical and Dental University |
DOUBLE-STRANDED NUCLEIC ACID COMPLEX WITH OVERHEAD
|
KR20190065341A
(ko)
|
2016-10-06 |
2019-06-11 |
아이오니스 파마수티컬즈, 인코포레이티드 |
올리고머 화합물들의 접합 방법
|
JOP20190104A1
(ar)
|
2016-11-10 |
2019-05-07 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن atxn3
|
AU2017368050A1
(en)
|
2016-11-29 |
2019-06-20 |
Puretech Lyt, Inc. |
Exosomes for delivery of therapeutic agents
|
EP3548620A4
(en)
|
2016-12-02 |
2020-07-22 |
Cold Spring Harbor Laboratory |
MODULATION OF THE EXPRESSION OF LNC05
|
CA3052801A1
(en)
|
2017-02-06 |
2018-08-09 |
Nissan Chemical Corporation |
Single-stranded oligonucleotide
|
EP3587576A4
(en)
*
|
2017-02-21 |
2021-01-06 |
Osaka University |
ANTI-SENSE OLIGONUCLEIC ACID
|
JOP20190215A1
(ar)
|
2017-03-24 |
2019-09-19 |
Ionis Pharmaceuticals Inc |
مُعدّلات التعبير الوراثي عن pcsk9
|
EP3647423A4
(en)
|
2017-06-30 |
2021-03-24 |
National University Corporation Tokyo Medical and Dental University |
DOUBLE STRANDED HETERO-ANTI-MIRNA
|
AU2018316159A1
(en)
|
2017-08-08 |
2020-02-06 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods thereof
|
AU2018318231A1
(en)
|
2017-08-18 |
2020-02-13 |
Ionis Pharmaceuticals, Inc. |
Modulation of the notch signaling pathway for treatment of respiratory disorders
|
SG10202108375XA
(en)
|
2017-08-25 |
2021-09-29 |
Stoke Therapeutics Inc |
Antisense oligomers for treatment of conditions and diseases
|
WO2019051173A1
(en)
|
2017-09-08 |
2019-03-14 |
Ionis Pharmaceuticals, Inc. |
MODULATORS OF SMAD7 EXPRESSION
|
WO2019073018A1
(en)
|
2017-10-13 |
2019-04-18 |
Roche Innovation Center Copenhagen A/S |
METHODS OF IDENTIFYING ANTISENSE OLIGONUCLEOTIDE IMPROVED OLIGONUCLEOTIDE PHOSPHOROTHIOATE STEREODEFINIS VARIANTS USING PARTIALLY STEREODEFINIS OLIGONUCLEOTIDE SUB LIBRARIES
|
CN111511914B
(zh)
|
2017-10-16 |
2023-11-17 |
豪夫迈·罗氏有限公司 |
减少PAPD5和PAPD7 mRNA的核酸分子用于治疗乙型肝炎感染
|
TWI809004B
(zh)
|
2017-11-09 |
2023-07-21 |
美商Ionis製藥公司 |
用於降低snca表現之化合物及方法
|
WO2019115416A2
(en)
|
2017-12-11 |
2019-06-20 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating fndc3b expression
|
WO2019115417A2
(en)
|
2017-12-12 |
2019-06-20 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating rb1 expression
|
WO2019126641A2
(en)
|
2017-12-21 |
2019-06-27 |
Ionis Pharmaceuticals, Inc. |
Modulation of frataxin expression
|
AU2018390167A1
(en)
|
2017-12-21 |
2020-06-11 |
F. Hoffmann-La Roche Ag |
Companion diagnostic for HTRA1 RNA antagonists
|
EP4074724A1
(en)
|
2017-12-22 |
2022-10-19 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides comprising a phosphorodithioate internucleoside linkage
|
AU2018386527A1
(en)
|
2017-12-22 |
2020-04-30 |
Roche Innovation Center Copenhagen A/S |
Gapmer oligonucleotides comprising a phosphorodithioate internucleoside linkage
|
KR20200104302A
(ko)
|
2017-12-22 |
2020-09-03 |
로슈 이노베이션 센터 코펜하겐 에이/에스 |
신규 티오포스포르아미다이트
|
US20210095274A1
(en)
|
2018-01-10 |
2021-04-01 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating pias4 expression
|
US20210095275A1
(en)
|
2018-01-12 |
2021-04-01 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating gsk3b expression
|
MA51645A
(fr)
|
2018-01-15 |
2020-11-25 |
Ionis Pharmaceuticals Inc |
Modulateurs de l'expression de dnm2
|
US20210095276A1
(en)
|
2018-01-17 |
2021-04-01 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating erc1 expression
|
JP2021511029A
(ja)
|
2018-01-18 |
2021-05-06 |
ロシュ イノベーション センター コペンハーゲン エーエス |
Srebp1を標的とするアンチセンスオリゴヌクレオチド
|
WO2019145386A1
(en)
|
2018-01-26 |
2019-08-01 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating csnk1d expression
|
SG11202007093YA
(en)
|
2018-02-09 |
2020-08-28 |
Genentech Inc |
Oligonucleotides for modulating tmem106b expression
|
AU2019218987A1
(en)
|
2018-02-12 |
2020-07-23 |
Ionis Pharmaceuticals, Inc. |
Modified compounds and uses thereof
|
US11674141B2
(en)
|
2018-02-28 |
2023-06-13 |
National University Corporation Tokyo Medical And Dental University |
Ischemic-lesion-site-specific gene therapy
|
EP3759127A4
(en)
|
2018-03-02 |
2022-03-30 |
Ionis Pharmaceuticals, Inc. |
COMPOUNDS AND METHODS FOR MODULATING AMYLOID BETA PRECURSOR PROTEIN
|
US11241451B2
(en)
|
2018-03-02 |
2022-02-08 |
Ionis Pharmaceuticals, Inc. |
Modulators of IRF4 expression
|
JP7394392B2
(ja)
|
2018-03-14 |
2023-12-08 |
国立大学法人 東京医科歯科大学 |
核酸複合体
|
JP7333079B2
(ja)
|
2018-03-19 |
2023-08-24 |
国立大学法人 東京医科歯科大学 |
毒性が軽減した核酸
|
AU2019237599A1
(en)
|
2018-03-20 |
2020-11-12 |
Nissan Chemical Corporation |
Antisense oligonucleotide having reduced toxicity
|
JP7262816B2
(ja)
|
2018-03-22 |
2023-04-24 |
国立大学法人 東京医科歯科大学 |
ヘテロ核酸のbbb通過脂質リガンド
|
WO2019183440A1
(en)
|
2018-03-22 |
2019-09-26 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating fmr1 expression
|
KR20200141481A
(ko)
|
2018-04-11 |
2020-12-18 |
아이오니스 파마수티컬즈, 인코포레이티드 |
Ezh2 발현의 조절제
|
US20210371860A1
(en)
|
2018-05-08 |
2021-12-02 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating myh7 expression
|
AU2019266307A1
(en)
|
2018-05-09 |
2020-11-19 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing ATXN3 expression
|
BR112020020957B1
(pt)
|
2018-05-09 |
2022-05-10 |
Ionis Pharmaceuticals, Inc |
Compostos oligoméricos, população e composição farmacêutica dos mesmos e seus usos
|
US11066669B2
(en)
|
2018-06-05 |
2021-07-20 |
Hoffmann-La Roche Inc. |
Oligonucleotides for modulating ATXN2 expression
|
JP2021526823A
(ja)
*
|
2018-06-14 |
2021-10-11 |
アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. |
Stmn2発現を増加させるための化合物及び方法
|
CN112400019B
(zh)
|
2018-06-27 |
2024-05-07 |
Ionis制药公司 |
用于减少lrrk2表达的化合物和方法
|
WO2020007772A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting gbp-1
|
WO2020007702A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting bcl2l11
|
WO2020007700A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting spi1
|
CR20210058A
(es)
|
2018-07-03 |
2021-03-22 |
Hoffmann La Roche |
Oligonucleótidos para modular la expresión de tau
|
WO2020007889A1
(en)
|
2018-07-05 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting stat1
|
WO2020007826A1
(en)
|
2018-07-05 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting mbtps1
|
WO2020011653A1
(en)
|
2018-07-09 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting kynu
|
WO2020011743A1
(en)
|
2018-07-09 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting mafb
|
WO2020011745A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting cers6
|
WO2020011869A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting tlr2
|
WO2020011744A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting cers5
|
AR115847A1
(es)
|
2018-07-25 |
2021-03-03 |
Ionis Pharmaceuticals Inc |
Compuestos y métodos para reducir la expresión de la atxn2
|
WO2020022499A1
(ja)
|
2018-07-27 |
2020-01-30 |
国立大学法人大阪大学 |
老化の抑制、加齢性の疾患もしくは症状の予防、改善、もしくは治療、または寿命の延長のための組成物
|
BR112020025272A2
(pt)
|
2018-07-31 |
2021-03-09 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotídeos, oligonucleotídeo gapmer, sal farmaceuticamente aceitável, conjugado, composição farmacêutica, usos de um oligonucleotídeo, método para o tratamento ou profilaxia de uma doença, processo para a fabricação de um oligonucleotídeo e invenção
|
WO2020025563A1
(en)
|
2018-07-31 |
2020-02-06 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides comprising a phosphorotrithioate internucleoside linkage
|
US11911484B2
(en)
|
2018-08-02 |
2024-02-27 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
KR20210081324A
(ko)
|
2018-08-02 |
2021-07-01 |
다인 세라퓨틱스, 인크. |
근육 표적화 복합체 및 안면견갑상완 근육 이영양증을 치료하기 위한 그의 용도
|
WO2020038973A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting sptlc1
|
WO2020038976A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting usp8
|
WO2020038971A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting vcan
|
EP3620519A1
(en)
|
2018-09-04 |
2020-03-11 |
F. Hoffmann-La Roche AG |
Use of isolated milk extracellular vesicles for delivering oligonucleotides orally
|
JP2022512877A
(ja)
|
2018-11-01 |
2022-02-07 |
エフ.ホフマン-ラ ロシュ アーゲー |
Tia1を標的とするアンチセンスオリゴヌクレオチド
|
TW202028222A
(zh)
|
2018-11-14 |
2020-08-01 |
美商Ionis製藥公司 |
Foxp3表現之調節劑
|
JOP20210108A1
(ar)
|
2018-11-15 |
2023-01-30 |
Ionis Pharmaceuticals Inc |
معدِّلات تعبير irf5
|
CN113330118A
(zh)
|
2018-12-21 |
2021-08-31 |
勃林格殷格翰国际有限公司 |
靶向card9的反义寡核苷酸
|
EP3914232A1
(en)
|
2019-01-25 |
2021-12-01 |
F. Hoffmann-La Roche AG |
Lipid vesicle for oral drug delivery
|
AU2020216444A1
(en)
|
2019-01-31 |
2021-07-29 |
Ionis Pharmaceuticals, Inc. |
Modulators of YAP1 expression
|
MX2021009950A
(es)
|
2019-02-20 |
2021-09-21 |
Roche Innovation Ct Copenhagen As |
Oligonucleotidos gapmeros de fosfonoacetato.
|
WO2020169696A1
(en)
|
2019-02-20 |
2020-08-27 |
Roche Innovation Center Copenhagen A/S |
Novel phosphoramidites
|
EP3931348B1
(en)
|
2019-02-26 |
2023-08-09 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide formulation method
|
EP3931328A4
(en)
|
2019-02-27 |
2023-09-13 |
Ionis Pharmaceuticals, Inc. |
MODULATORS OF MALAT1 EXPRESSION
|
US20220162607A1
(en)
|
2019-03-14 |
2022-05-26 |
Rena Therapeutics Inc. |
Nucleic acid complex for modulating ihh expression
|
PE20220284A1
(es)
|
2019-03-29 |
2022-02-25 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para modular ube3a-ats
|
US11286485B2
(en)
|
2019-04-04 |
2022-03-29 |
Hoffmann-La Roche Inc. |
Oligonucleotides for modulating ATXN2 expression
|
JPWO2020209285A1
(ja)
|
2019-04-08 |
2020-10-15 |
|
|
WO2020245233A1
(en)
|
2019-06-06 |
2020-12-10 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting atxn3
|
EP3956450A4
(en)
|
2019-07-26 |
2022-11-16 |
Ionis Pharmaceuticals, Inc. |
COMPOUNDS AND METHODS FOR MODULATION OF GFAP
|
JPWO2021054370A1
(ja)
|
2019-09-18 |
2021-03-25 |
|
|
JPWO2021070959A1
(ja)
|
2019-10-11 |
2021-04-15 |
|
|
JPWO2021070494A1
(ja)
|
2019-10-11 |
2021-04-15 |
|
|
US20220251557A1
(en)
*
|
2019-11-27 |
2022-08-11 |
Tokyo Institute Of Technology |
Method for reducing toxicity of antisense nucleic acids
|
MX2022007908A
(es)
|
2019-12-24 |
2022-07-21 |
Hoffmann La Roche |
Combinacion farmaceutica de un oligonucleotido terapeutico que actua sobre hbv y un agonista de tlr7 para el tratamiento de hbv.
|
JP2023509872A
(ja)
|
2019-12-24 |
2023-03-10 |
エフ. ホフマン-ラ ロシュ アーゲー |
Hbvを標的とする抗ウイルス剤及び/又はhbvの処置のための免疫調節剤の医薬組合せ
|
US20230090446A1
(en)
|
2020-01-28 |
2023-03-23 |
Universite De Strasbourg |
Antisense oligonucleotide targeting linc00518 for treating melanoma
|
WO2021153770A1
(en)
|
2020-01-29 |
2021-08-05 |
Sumitomo Chemical Company, Limited |
Process of preparing nucleic acid oligomer
|
KR20220133878A
(ko)
|
2020-01-29 |
2022-10-05 |
스미또모 가가꾸 가부시끼가이샤 |
핵산 올리고머의 제조 방법
|
EP4098747A1
(en)
|
2020-01-31 |
2022-12-07 |
Sanwa Kagaku Kenkyusho Co., Ltd. |
Antisense oligonucleotide of atn1
|
KR20220148230A
(ko)
|
2020-02-28 |
2022-11-04 |
아이오니스 파마수티컬즈, 인코포레이티드 |
Smn2를 조절하기 위한 화합물 및 방법
|
EP4116419A1
(en)
|
2020-03-04 |
2023-01-11 |
Nissan Chemical Corporation |
Antisense oligonucleotide of calm2
|
WO2021178374A2
(en)
*
|
2020-03-05 |
2021-09-10 |
Synerk Inc. |
Compounds and methods for reducing apoe expression
|
WO2021187392A1
(ja)
|
2020-03-16 |
2021-09-23 |
国立大学法人東京医科歯科大学 |
モルホリノ核酸を含むヘテロ核酸
|
JPWO2021193954A1
(ja)
|
2020-03-27 |
2021-09-30 |
|
|
WO2021222768A2
(en)
|
2020-05-01 |
2021-11-04 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating atxn1
|
US20230287410A1
(en)
|
2020-05-11 |
2023-09-14 |
Stoke Therapeutics, Inc. |
Opa1 antisense oligomers for treatment of conditions and diseases
|
WO2022006134A2
(en)
|
2020-06-29 |
2022-01-06 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating plp1
|
JPWO2022009959A1
(ja)
|
2020-07-09 |
2022-01-13 |
|
|
EP4219520A1
(en)
|
2020-09-24 |
2023-08-02 |
Sumitomo Chemical Company, Limited |
Method for producing nucleic acid oligomer
|
KR20230108728A
(ko)
|
2020-11-18 |
2023-07-18 |
아이오니스 파마수티컬즈, 인코포레이티드 |
앤지오텐시노겐 발현을 조절하기 위한 화합물 및 방법
|
WO2022117747A2
(en)
|
2020-12-03 |
2022-06-09 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting atxn3
|
AR124229A1
(es)
|
2020-12-03 |
2023-03-01 |
Hoffmann La Roche |
Oligonucleótidos antisentido que actúan sobre atxn3
|
WO2022162015A1
(en)
|
2021-01-26 |
2022-08-04 |
Universite Brest Bretagne Occidentale |
Novel stim1 splicing variants and uses thereof
|
JP2024518068A
(ja)
|
2021-05-10 |
2024-04-24 |
エントラーダ セラピューティクス,インコーポレイティド |
細胞内治療のための組成物及び方法
|
CA3219942A1
(en)
*
|
2021-05-10 |
2022-11-17 |
Q-State Biosciences, Inc. |
Compositions targeting sodium channel 1.6
|
WO2022250050A1
(ja)
|
2021-05-25 |
2022-12-01 |
国立大学法人東京医科歯科大学 |
scpBNA又はAmNAを含むヘテロ核酸
|
EP4353266A1
(en)
|
2021-05-31 |
2024-04-17 |
Rena Therapeutics Inc. |
Ligand-bound nucleic acid complex
|
CA3223192A1
(en)
|
2021-06-18 |
2022-12-22 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing ifnar1 expression
|
KR20240038967A
(ko)
|
2021-06-23 |
2024-03-26 |
엔트라다 테라퓨틱스, 인크. |
Cug 반복을 표적화하기 위한 안티센스 화합물 및 방법
|
US11638761B2
(en)
|
2021-07-09 |
2023-05-02 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
|
US11633498B2
(en)
|
2021-07-09 |
2023-04-25 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
JPWO2023022229A1
(ja)
|
2021-08-19 |
2023-02-23 |
|
|
JPWO2023026994A1
(ja)
|
2021-08-21 |
2023-03-02 |
|
|
US11833221B2
(en)
|
2021-09-01 |
2023-12-05 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds for reducing DMPK expression
|
WO2023042876A1
(ja)
|
2021-09-15 |
2023-03-23 |
国立大学法人東京医科歯科大学 |
2'-修飾ヌクレオシドを含むヘテロ核酸
|
WO2023078883A1
(en)
|
2021-11-03 |
2023-05-11 |
F. Hoffmann-La Roche Ag |
Oligonucleotides for modulating apolipoprotein e4 expression
|
WO2023083906A2
(en)
|
2021-11-11 |
2023-05-19 |
F. Hoffmann-La Roche Ag |
Pharmaceutical combinations for treatment of hbv
|
WO2023117738A1
(en)
|
2021-12-20 |
2023-06-29 |
F. Hoffmann-La Roche Ag |
Threose nucleic acid antisense oligonucleotides and methods thereof
|
WO2023141507A1
(en)
|
2022-01-20 |
2023-07-27 |
Genentech, Inc. |
Antisense oligonucleotides for modulating tmem106b expression
|
WO2023178144A2
(en)
|
2022-03-16 |
2023-09-21 |
Empirico Inc. |
Galnac compositions for improving sirna bioavailability
|
US11931421B2
(en)
|
2022-04-15 |
2024-03-19 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and formulations for treating myotonic dystrophy
|
WO2024026474A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
|
WO2024050261A1
(en)
|
2022-08-29 |
2024-03-07 |
University Of Rochester |
Antisense oligonucleotide-based anti-fibrotic therapeutics
|
EP4332221A1
(en)
|
2022-08-29 |
2024-03-06 |
Roche Innovation Center Copenhagen A/S |
Threose nucleic acid antisense oligonucleotides and methods thereof
|
WO2024073386A1
(en)
*
|
2022-09-29 |
2024-04-04 |
Celanese Eva Performance Polymers Llc |
Implantable medical device for the delivery of a nucleic acid
|